United States

Takara Bio Inc (4974.T)

4974.T on Tokyo Stock Exchange

19 Sep 2017
Change (% chg)

¥15 (+0.99%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


TAKARA BIO INC. is a biotechnological company. The Company has three business segments. The Genetic Engineering Research segment is involved in the research and development of biotechnology; the manufacture of research reagents; the sale, maintenance and repair of physics and chemistry equipment, such as reaction temperature... (more)


Beta: 1.78
Market Cap(Mil.): ¥182,068.41
Shares Outstanding(Mil.): 120.42
Dividend: --
Yield (%): 0.26


  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Takara Bio starts first test of Phase II clinical trial of HF10

* Says it started first test of Phase II clinical trial of HF10, which will be used for treatment in patients with unresectable or metastatic melanoma, on May 26

May 29 2017

BRIEF-Takara Holdings' subsidiary Takara Bio says merger between US-based units

* Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively

Mar 27 2017

Earnings vs. Estimates